[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 54 of about 54
1. Fujiwara A, Shibata E, Terashima H, Shishido A, Nishiki J, Yoshida K, Miyauchi K, Madachi A, Matsuura N: Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors. Breast Cancer; 2006;13(3):272-8
Hazardous Substances Data Bank. GELATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors.
  • BACKGROUND: Fine-needle aspiration (FNA) biopsy of breast tumors is a reliable diagnostic method for identifying breast carcinoma.
  • To improve the cytological diagnosis of breast tumors, we investigated the expression of active matrix metalloproteinase-2 (MMP-2), as detected by film in situ zymography (FIZ).
  • METHODS: We evaluated 34 fresh breast tumors, 25 paraffin-embedded breast tissue specimens, and a human cancer cell line (HT1080).
  • Frozen sections and aspiration cytology samples of breast cancer were incubated on gelatin-coated films for the detection of active MMP-2.
  • RESULTS: Immunohistochemistry showed that MMP-2 was expressed in cancer cells and stromal cells, but not in most benign breast lesions.
  • Gelatinolytic activity was also detected by FIZ analysis of aspiration cytology samples and frozen sections from the breast cancers, and there was a significant correlation between this gelatinolytic activity and the detection of MMP-2 expression by immunocytochemistry.
  • CONCLUSIONS: The present study demonstrated that measurement of gelatinolytic activity by FIZ analysis of aspiration cytology samples may be useful for improving the cytological diagnosis of breast tumors.
  • [MeSH-major] Breast Neoplasms / enzymology. Gelatin / metabolism. Matrix Metalloproteinase 2 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / enzymology. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / enzymology. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / enzymology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929121.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / gelatin film; 9000-70-8 / Gelatin; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


2. Anderson WF, Devesa SS: In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer; 2005 Oct 15;104(8):1733-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute.
  • BACKGROUND: In situ breast carcinoma is not so well characterized for men as for women.
  • METHODS: Therefore, the authors of the current study compared male and female in situ and invasive breast carcinomas in the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute to document these patterns.
  • RESULTS: In situ breast carcinomas composed 9.4% of all male (n = 280 of 2984) and 11.9% of all female breast carcinomas (n = 53,928 of 454,405) during the years 1973-2001.
  • In situ rates rose 123% for men and 555% for women over this time period; whereas distant disease rates fell for both genders.
  • Median ages at diagnosis were 62 years for in situ and 68 years for invasive breast carcinoma among men, compared with 58 years for in situ and 62 years for invasive breast carcinoma among women.
  • Papillary in situ and invasive architectural types were more common among men than women.
  • Breast cancer-specific survival was similar among men and women, whereas overall survival was worse for men than women.
  • CONCLUSION: In situ male breast carcinoma is a rare disease, occurring at older ages and with different architectural types than its more common female counterpart.
  • Gender-specific histopathologic differences probably reflect anatomic differences among the normal female and vestigial male breast.
  • Rising in situ male breast carcinoma incidence rates over the past three decades suggest earlier detection over time, irrespective of mammography, because men do not participate in routine screening mammography.
  • [MeSH-major] Breast Neoplasms, Male / epidemiology. SEER Program / statistics & numerical data
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Ductal, Lobular, and Medullary / epidemiology. Risk Factors. Survival Rate. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16138363.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


3. Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R: TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology; 2010 Jul;57(1):81-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
  • AIMS: Topoisomerase IIalpha (TOPOIIalpha) and HER-2/neu are chromosome 17q genes coamplified in various cancers; no data exist for Barrett's oesophagus (BO) and BO adenocarcinoma (ADC).
  • METHODS AND RESULTS: Forty-four patients [18 BO, 13 BO with dysplasia (five low-grade dysplasia, eight high-grade dysplasia) and 13 ADC in BO] were evaluated by immunohistochemistry and fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antigens, Neoplasm / genetics. Barrett Esophagus / genetics. Barrett Esophagus / pathology. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Genes, erbB-2
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Chromosomes, Human, Pair 17 / genetics. Diagnosis, Differential. Female. Gene Amplification. Gene Expression. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2006;53(5):393-401 [17013533.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):305-11 [17307036.001]
  • [Cites] Mod Pathol. 2007 May;20(5):584-91 [17396141.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):768-72 [16882699.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5115-23 [17785566.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):403-9 [18261624.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Dec;54(4):347-53 [19047975.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3826-33 [19292734.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Anal Cell Pathol. 2000;20(1):25-32 [11007435.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8 [11121461.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):890-2 [11265171.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):179-86 [14499010.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):288-97 [14978790.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):233-7 [14990588.001]
  • [Cites] Neoplasma. 2004;51(3):193-7 [15254672.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):63-70 [1980607.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):195-211 [7795268.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):761-8 [9284825.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1180-8 [9343325.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60 [9747866.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):28-35 [15762277.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • (PMID = 20557373.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2916224
  •  go-up   go-down


Advertisement
4. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res; 2005 May 15;11(10):3766-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
  • PURPOSE: Patients with metastatic adenocarcinoma of unknown origin are a common clinical problem.
  • In the first (training) round, we studied 352 primary adenocarcinomas, from seven main sites (breast, colon, lung, ovary, pancreas, prostate and stomach) and their differential diagnoses.
  • CONCLUSIONS: This classification scheme should enable better prediction on biopsy material of the primary site in patients with metastatic adenocarcinoma of unknown origin, leading to improved management and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Predictive Value of Tests. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897574.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, Hainfeld JF, Tubbs RR: Metallographic in situ hybridization. Hum Pathol; 2007 Aug;38(8):1145-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallographic in situ hybridization.
  • Metallographic methods, in which a target is visualized using a probe or antibody that deposits metal selectively at its binding site, offers many advantages for bright-field in situ hybridization (ISH) detection as well as for other labeling and detection methods.
  • Enzyme metallography, a novel procedure in which an enzymatic probe is used to deposit metal directly from solution, has been used to develop bright-field ISH methods for HER2 gene determination in breast cancer and other biopsy specimens.
  • [MeSH-major] Gold Colloid / chemistry. In Situ Hybridization / methods. Nucleic Acids / chemistry. Silver Compounds / chemistry. Silver Staining / methods
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Breast Neoplasms / chemistry. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Enzymes / chemistry. Female. Humans. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / genetics

  • Hazardous Substances Data Bank. SILVER COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640553.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R43CA111182-01; United States / NCI NIH HHS / CA / 5R42CA83618-03; United States / NIGMS NIH HHS / GM / 5R44 GM064257-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzymes; 0 / Gold Colloid; 0 / Nucleic Acids; 0 / Silver Compounds; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 125
  •  go-up   go-down


6. Popnikolov NK, Cavone SM, Schultz PM, Garcia FU: Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol; 2005 Dec;18(12):1535-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • We evaluated the low affinity neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • Immunohistochemical staining for p75NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue.
  • The staining pattern was compared to those of myosin heavy chain and p63. p75NTR immunostain was consistently positive and compatible with p63 and myosin immunoreactivity in the myoepithelial cells of the normal mammary gland, benign breast lesions (six usual ductal hyperplasias, six specimens with sclerosing adenosis, eight intraductal papillomas, six fibroadenomas), and carcinoma in situ (18 ductal carcinomas in situ, two noninvasive papillary carcinomas, two lobular carcinomas in situ).
  • No p75NTR expression was found in the malignant cells in all in situ carcinomas, invasive lobular carcinomas (n = 11), tubular carcinomas (n = 10), invasive papillary carcinomas (n = 6), mucinous carcinomas (n = 4), and medullary carcinomas (n = 2).
  • Our study shows that p75NTR is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease as well as to evaluate difficult for diagnosis sclerosing lesions.
  • Our data suggest a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology. Muscle, Smooth / pathology. Receptor, Nerve Growth Factor / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Myosin Heavy Chains / metabolism. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258511.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


7. Park MJ, Cha ES, Kang BJ, Ihn YK, Baik JH: The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors. Korean J Radiol; 2007 Sep-Oct;8(5):390-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors.
  • OBJECTIVE: We wanted to evaluate the role of diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) for detecting breast tumors, as compared with the T1- and T2-weighted images.
  • MATERIALS AND METHODS: Forty-one female patients underwent breast MRI, and this included the T1-, T2-, DWI and dynamic contrast-enhanced images.
  • Fifty-six breast lesions were detected on DWI and the histological diagnoses were as follows: 43 invasive ductal carcinomas, one mucinous carcinoma, one mixed infiltrative and mucinous carcinoma, seven ductal carcinomas in situ (DCIS), and four benign tumors.
  • First, we compared the detectability of breast lesions on DWI with that of the T1- and T2-weighted images.
  • We then compared the ADCs of the malignant and benign breast lesions to the ADCs of the normal fibroglandular tissue.
  • The detectabilities of breast lesions on the T1- and T2-weighted imaging were 61.5% (40/65) and 75.4% (49/65), respectively.
  • CONCLUSION: DWI has a high sensitivity for detecting breast tumors, and especially for detecting malignant breast tumors.
  • DWI was an effective imaging technique for detecting breast lesions, as compared to using the T1- and T2-weighted images.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Breast / pathology. Contrast Media / administration & dosage. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Imaging, Three-Dimensional / methods. Middle Aged. Observer Variation. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):975-83 [11105039.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Radiology. 2001 Jul;220(1):13-30 [11425968.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1403-9 [12034606.001]
  • [Cites] J Magn Reson Imaging. 2002 Jun;15(6):693-704 [12112520.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] J Comput Assist Tomogr. 2002 Nov-Dec;26(6):1042-6 [12488758.001]
  • [Cites] Eur J Radiol. 2003 Mar;45(3):169-84 [12595101.001]
  • [Cites] Radiology. 2003 Oct;229(1):225-32 [14519877.001]
  • [Cites] J Magn Reson Imaging. 2004 Oct;20(4):654-61 [15390142.001]
  • [Cites] Stroke. 1997 Mar;28(3):481-2 [9056599.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):397-402 [9456953.001]
  • [Cites] Radiology. 1998 Sep;208(3):605-9 [9722835.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):393-8 [10430143.001]
  • [Cites] JAMA. 2004 Dec 8;292(22):2735-42 [15585733.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):1014-9 [11105044.001]
  • (PMID = 17923781.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2626812
  •  go-up   go-down


8. Uzan C, Andre F, Scott V, Laurent I, Azria E, Suciu V, Balleyguier C, Lacroix L, Delaloge S, Vielh P: Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer. Cancer; 2009 Feb 25;117(1):32-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer.
  • METHODS: Ultrasound- or palpation-guided FNAC was performed in 124 consecutive patients who had nodular breast lesions.
  • For malignant lesions, the authors attempted to correlate estrogen receptor 1 (ESR1) and HER-2 (c-erb-B2) mRNA expression measured by real-time quantitative polymerase chain reaction with estrogen receptor and HER-2 detection obtained by immunohistochemistry (IHC) and/or fluorescent in situ hybridization (FISH) on the surgical specimen.
  • The most significant predictors of quality and quantity of mRNA were the cytopathologist who sampled the tumors and a diagnosis of cancer versus benign lesion.
  • CONCLUSIONS: In 70% of cases, FNAC of breast lesions in well trained hands allowed the extraction of mRNA suitable for gene expression analysis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Breast Neoplasms / diagnosis. RNA, Messenger / isolation & purification
  • [MeSH-minor] Estrogen Receptor alpha / biosynthesis. Estrogen Receptor alpha / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19347827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


9. Sahoo S, Recant WM: Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast. Breast J; 2005 Mar-Apr;11(2):140-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast.
  • Columnar cell alteration in the breast encompasses a spectrum of pathologic changes ranging from simple columnar cell change to more complex columnar cell hyperplasia with and without atypia to in situ carcinoma, often with a micropapillary architecture.
  • For reasons that remain unclear, the columnar cell lesions are associated with tubular carcinomas and lobular carcinoma in situ.
  • Therefore it is important to be familiar with the spectrum of changes and the associated lesions, especially in breast core biopsies for further management.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Breast / pathology. Calcinosis / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730461.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • CASE: A 45-year-old woman who received radiotherapy for ductal carcinoma in situ (DCIS) 5 years previously had a local recurrence a year earlier and recent development of bilateral small pulmonary nodules.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • The original breast tumor was typical of cribriform DCIS.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152281.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Gu M, Ghafari S, Zhao M: Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol; 2005 Sep-Oct;49(5):471-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
  • OBJECTIVE: To assess the usefulness of fluorescence in situ hybridization (FISH) for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy (FNAB) specimens.
  • RESULTS: FISH was performed on 41 surgical specimens of breast carcinoma.
  • Thirteen patients had prior FNABs that were positive for adenocarcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Gene Amplification / genetics. Genes, erbB-2 / genetics. In Situ Hybridization, Fluorescence / methods. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334021.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


12. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst; 2005 Jan 19;97(2):142-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.
  • BACKGROUND: The incidence of esophageal adenocarcinoma is rising dramatically.
  • METHODS: We used the National Cancer Institute's Surveillance, Epidemiology, and End Results database to extract information on incidence, stage distribution, and disease-specific mortality for esophageal adenocarcinoma as well as information on related cancers.
  • RESULTS: From 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from 4 to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer.
  • The only location with increased incidence is the lower third of the esophagus-the site where adenocarcinoma typically arises.
  • Because there has been little change in the proportion of patients found with in situ or localized disease at diagnosis since 1975 (from 25% to 31%) and because esophageal adenocarcinoma mortality has increased more than sevenfold (from 2 to 15 deaths per million), overdiagnosis can be excluded as an explanation for the rise in incidence.
  • CONCLUSION: The rising incidence of esophageal adenocarcinoma represents a real increase in disease burden.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / epidemiology. Esophageal Neoplasms / classification. Esophageal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Classification / methods. Confounding Factors (Epidemiology). Cost of Illness. Cross-Sectional Studies. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. SEER Program. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Jul 6;97(13):1013-4; author reply 1014 [15998956.001]
  • (PMID = 15657344.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


13. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Specific histologic diagnoses included intraductal papilloma (2 cases), and in situ lobular neoplasia (2 cases).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Chen CH, Rowlands C, Sengupta SK, George RL, Parulekar W, Thain K, O'Malley F, Isotalo PA: Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ. Breast J; 2009 Jul-Aug;15(4):409-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ.
  • We describe a primary invasive adenocarcinoma of the nipple with extensive basaloid features that was also associated with squamous cell carcinoma (SCC) in situ and an aggressive behavior.
  • A 69-year-old woman without a history of breast neoplasia presented with right nipple pain.
  • Biopsy of the nipple revealed SCC in situ.
  • SCC in situ was present in the overlying epidermis.
  • The differential diagnosis included a primary basaloid adenocarcinoma of the nipple, basal cell carcinoma of the nipple, neuroendocrine carcinoma, melanoma, basaloid variant of adenoid cystic carcinoma and metastatic disease.
  • Immunohistochemical profile of this tumor supported a primary basaloid adenocarcinoma of the nipple.
  • Although the initial sentinel lymph node biopsy was negative, within a year of diagnosis, the patient developed ipsilateral axillary node and pulmonary metastases.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Nipples / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601946.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Gadre SA, Perkins GH, Sahin AA, Sneige N, Deavers MT, Middleton LP: Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology; 2008 Nov;53(5):545-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion.
  • AIMS: Ductal carcinoma in situ (DCIS) associated with invasive mucinous carcinoma (IMC) has not been well characterized.
  • The aim was to characterize mucinous DCIS (mDCIS) of the breast and to describe, to our knowledge for the first time, neovascularization in mucin.
  • Anderson Cancer Center, whose diagnosis fulfilled the criteria of IMC or DCIS with mucin production.
  • When identified on core needle biopsy, the presence of vascularized mucin should not be used alone to discriminate between invasive and in situ carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / blood supply. Carcinoma, Intraductal, Noninfiltrating / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983463.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Mucins; 0 / Trans-Activators; 0 / Vascular Endothelial Growth Factor A; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


16. Brandt SM, Young GQ, Hoda SA: The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv Anat Pathol; 2008 May;15(3):140-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions.
  • The histologic triad of tubular carcinoma (TC), columnar cell lesion (CCL), and lobular carcinoma in situ (LCIS) has been recognized, but has not yet been fully characterized.
  • The diagnosis of TC was confirmed in 86 of our cases, and relevant patient data were analyzed.
  • On the basis of our review of the literature and our own experience, until such time as the biologic explanation and clinical implication of this triad is further elucidated, we recommend that pathologists be aware of this triad and should proactively seek the other 2 lesions if any one of these elements of this triad is identified in any diagnostic breast tissue.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Lobular / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434766.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


17. Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M: Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer; 2008;15(4):315-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases.
  • Breast metastases from extra-mammary malignancies, especially those mimicking primary inflammatory breast carcinoma, are extremely rare.
  • We report here two cases of inflammatory breast metastases from gastric or ovarian cancer.
  • Both patients, who had prior advanced malignant disease, presented with unilateral breast redness and swelling with peau d'orange sign, resembling primary inflammatory breast cancer or acute mastitis.
  • Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively.
  • Immunohistochemical staining for estrogen receptor, progesterone receptor, and gross cystic disease fluid protein 15 was of value for correct diagnosis.
  • Since breast metastasis is a sign of poor prognosis of the primary malignant disease, the possibility of breast metastasis should be considered in appropriate patients to preclude unnecessary major surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed


18. Wheeler DT, Kurman RJ: The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma. Int J Gynecol Pathol; 2005 Apr;24(2):125-30
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma.
  • Routinely stained slides were examined from 50 invasive endocervical adenocarcinomas (37 of usual type and 13 of minimal deviation type), 26 noninvasive lesions (14 cases of adenocarcinoma in situ, 7 cases of hyperplasia, 4 cases of tunnel clusters, 1 adenomyoma), and 20 normal cervices, including 7 with deep nabothian cysts.
  • In conclusion, close proximity of glands to thick-wall blood vessels (distance from the closest gland to a thick-wall vessel less than or equal to the thickness of the vessel wall) seems to be a useful feature in the diagnosis of invasive endocervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor. Cervix Uteri / blood supply. Neoplasm Invasiveness / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782068.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Ding HY, Yang GZ: [Clinicopathological features of the mucocele-like lesions in the breast]. Zhonghua Bing Li Xue Za Zhi; 2008 Jan;37(1):31-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological features of the mucocele-like lesions in the breast].
  • OBJECTIVE: To study the clinical and pathological features of mucocele-like lesions in the breast.
  • METHODS: Nine cases of mucocele-like lesions in the breast were reported for the morphological and immunohistochemical features, the differential diagnosis, and a literature review.
  • RESULTS: All nine cases were from female patients, aged 23 to 43 years (mean 34 years), clinically presented with palpable breast masses.
  • CONCLUSION: Mucocele-like lesions of the breast is a group of mostly benign disease, and the differential diagnosis should include mucinous carcinoma.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Hyperplasia / pathology. Mucocele / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / diagnosis. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Intestinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509982.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Matei M, Azoicăi D: [Histopathological characteristics of genital and breast cancer included in epidemiologic study cohort]. Rev Med Chir Soc Med Nat Iasi; 2009 Apr-Jun;113(2):540-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathological characteristics of genital and breast cancer included in epidemiologic study cohort].
  • The correct management of genitals and breast cancers and the improving of the preventional and therapeutical successes ratio involve the knowledge of the histopathological features of these nosological entities which have different origins, different risk factors, different simptomatology and also different prognosis.
  • AIM: The descriptive evaluation of the histopathological features of the genitals and breast cancers to women from North-Eastern region of Romania.
  • MATERIAL AND METHOD: We have been included in the study 96 women (age range 23-77 years, mean 54,49) diagnosed with breast cancer, ovarian cancer, endometrial cancer and cervical cancer at the hospital admission, residency in the Obstetrics and Gynecology Clinics within 23 months.
  • The following main parameters were assessed: histological types, stage at diagnosis, Pap test.
  • RESULTS: The following cases' repartition on diagnostic types was observed: breast cancer (44 cases), cervical cancer (24 cases), endometrial cancer (16 cases) and ovarian cancer (12 cases).
  • In our study, the most affected range of age was 40-69 years for breast cancer, 30-59 years for cervical cancer, over 6 years for endometrial cancer and 50-59 years for ovarian cancer.
  • For the cervical neoplasia, 40% of analyzed cases were in incipient stages (in situ to IB stage lessions).
  • More than 50% of breast cancer cases have been diagnosed in advances stages (IIB to IIIC stages).
  • For the endometrium carcinoma, 45% of cases have been identified in incipient stages (in situ to IC).
  • CONCLUSION: From a histopathological point of view, for cervical neoplasia, squamous carcinoma was the most frequent type (87%), for breast neoplasia--invasive ductal carcinoma (80%) and for ovary and endometrium malignant tumors--adenocarcinoma (69%, respectively 83%).
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology. Genital Neoplasms, Female / epidemiology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Cohort Studies. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / pathology. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / pathology. Prognosis. Risk Factors. Romania / epidemiology. Uterine Neoplasms / epidemiology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495363.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


21. Tan PH, Tse GM, Bay BH: Mucinous breast lesions: diagnostic challenges. J Clin Pathol; 2008 Jan;61(1):11-9
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous breast lesions: diagnostic challenges.
  • Breast lesions with mucin represent a broad spectrum of entities, ranging from benign fibrocystic changes with luminal mucin to mucocele-like lesions (MLL), which can be associated with banal epithelial alterations, atypical ductal hyperplasia or ductal carcinoma in situ.
  • [MeSH-major] Breast Diseases / pathology. Breast Neoplasms / pathology. Mucins / analysis
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Breast / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / pathology. Mucocele / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873114.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 52
  •  go-up   go-down


22. Trop I, David J, Lalonde L: Breast cancer staging: the role of the radiologist. Can Assoc Radiol J; 2005 Dec;56(5):324-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer staging: the role of the radiologist.
  • The role of the breast radiologist has evolved over the past years, with an increasing involvement in patient care.
  • This article reviews the elements of investigation that are important to the surgeon and oncologist in optimizing care for the newly diagnosed breast cancer patient, with the 6th edition of the TNM classification of the American Joint Committee on Cancer used as a reference.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Lymph Nodes / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Breast Diseases / pathology. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Mammography. Middle Aged. Nipples / pathology. Prognosis. Risk Factors. Sensitivity and Specificity. Sentinel Lymph Node Biopsy. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579027.001).
  • [ISSN] 0846-5371
  • [Journal-full-title] Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
  • [ISO-abbreviation] Can Assoc Radiol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 15
  •  go-up   go-down


23. Rossi E, Villanacci V, Bassotti G, Casa DD, Missale G, Minelli L, Cestari R: Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol; 2006 Sep;15(3):125-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
  • Her-2/neu is a protooncogene frequently overexpressed in breast cancer, recently found to be also overexpressed in carcinoma arising on Barrett esophagus (BE).
  • Immunohistochemistry and fluorescence in situ hybridization (FISH) are conventionally used for Her-2 testing in carcinomas, but a single assay is not yet accepted as a "gold standard" in BE.
  • To evaluate the correlation between histopathology variables and gene expression/amplification in the sequence BE-low grade dysplasia-high grade dysplasia-adenocarcinoma, fifty esophageal specimens from patients with a diagnosis of BE (21 BE, 4 low-grade dysplasia, 12 high-grade dysplasia, and 13 adenocarcinomas) were evaluated.
  • [MeSH-major] Barrett Esophagus / diagnosis. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Aged. Female. Gene Amplification. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. RNA, Messenger / analysis. RNA, Messenger / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932066.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


24. Goodman MT, Tung KH, Wilkens LR: Comparative epidemiology of breast cancer among men and women in the US, 1996 to 2000. Cancer Causes Control; 2006 Mar;17(2):127-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative epidemiology of breast cancer among men and women in the US, 1996 to 2000.
  • OBJECTIVE: Few investigations of breast cancer among men have been conducted because of the relative rarity of this malignancy.
  • The objective of this analysis was to compare the demographic, pathological, and clinical features of breast cancer among men and women.
  • METHODS: Breast cancer among 6379 men and 744,275 women was identified through 34 US population-based registries in the US during the period 1996 to 2000.
  • RESULTS: The AAIR of breast cancer among men (16.6) was substantially lower than the incidence among women (1557.7).
  • Rates of breast cancer among black men were higher than among white and Asian-Pacific Island men, in contrast to women among whom rates in whites exceeded those among other ethnic groups.
  • Similar to women, breast cancer rates among non-Hispanic men were 50% greater than among Hispanic men.
  • Lobular breast cancers were less common among black men and women than among other ethnic groups.
  • In situ breast cancer was diagnosed in 10.8% of men and 16.2% of women.
  • Localized breast cancer was the most common stage at diagnosis in both sexes and all ethnic groups, although women were more likely than men to be diagnosed at a localized stage.
  • Cancer was 10% more likely to be diagnosed in the left breast than the right breast among men compared to 4% in women.
  • CONCLUSIONS: In spite of the rare incidence of breast cancer in men, the descriptive epidemiology of this malignancy is surprisingly similar to that in women.
  • An explanation for the greater relative incidence of breast cancer in black men is a research challenge.
  • [MeSH-major] Adenocarcinoma / epidemiology. Breast Neoplasms / epidemiology. Registries
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / ethnology. Child. Female. Humans. Incidence. Male. Middle Aged. Sex Distribution. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425090.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67001; United States / PHS HHS / / U75/CCU515998
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


25. Louie LD, Crowe JP, Dawson AE, Lee KB, Baynes DL, Dowdy T, Kim JA: Identification of breast cancer in patients with pathologic nipple discharge: does ductoscopy predict malignancy? Am J Surg; 2006 Oct;192(4):530-3
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of breast cancer in patients with pathologic nipple discharge: does ductoscopy predict malignancy?
  • OBJECTIVE: The purpose of the current study was to review characteristics of patients with nipple discharge who underwent ductoscopy-assisted excisional biopsy who had a final diagnosis of carcinoma.
  • METHODS: A retrospective review was performed of patients presenting with pathologic nipple discharge (PND) who underwent ductoscopy-assisted excisional biopsy and had a final diagnosis of carcinoma.
  • RESULTS: A total of 14 (7%) of 188 patients who underwent ductoscopy-assisted excision had a final pathology of ductal carcinoma-in-situ (DCIS) (12/14, 86%) or invasive breast cancer with DCIS (2/14, 14%).
  • Duct wall irregularities or intraluminal growths were visualized during ductoscopy in 8 of the 14 (57%) breast cancer patients.
  • There were no visual abnormalities noted during ductoscopy that accurately predicted a final diagnosis of malignancy.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Endoscopy. Exudates and Transudates / secretion. Mammary Glands, Human / pathology. Nipples / secretion

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978968.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Tanaka K, Komoike Y, Egawa C, Motomura K, Koyama H, Nagumo S, Kataoka TR, Inaji H: Indeterminate calcification and clustered cystic lesions are strongly predictive of the presence of mucocele-like tumor of the breast: a report of six cases. Breast Cancer; 2009;16(1):77-82
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indeterminate calcification and clustered cystic lesions are strongly predictive of the presence of mucocele-like tumor of the breast: a report of six cases.
  • Mucocele-like tumor (MLT) of the breast is a mucinous disorder that is generally difficult to distinguish from mucinous carcinoma.
  • Moreover, MLT is often accompanied by atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS), and preoperative diagnosis is very confusing.
  • Ultimately, excisional biopsies were performed to obtain a correct diagnosis in all cases.
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology. Calcinosis / pathology. Mucocele / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Biopsy, Fine-Needle. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478314.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Hicks DG, Kulkarni S: HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol; 2008 Feb;129(2):263-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
  • Clinical laboratory testing for human epidermal growth factor receptor 2 (HER2) status in newly diagnosed breast cancer is critically important for therapeutic decision making.
  • Unlike most pathologic testing, which serves as an adjunct to establishing a diagnosis, the results of HER2 testing stand alone in determining which patients are likely to respond to trastuzumab, a monoclonal antibody against HER2.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Genes, erbB-2
  • [MeSH-minor] Algorithms. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Guidelines as Topic. Humans. Immunohistochemistry / standards. In Situ Hybridization, Fluorescence / standards. Laboratories / standards. Quality Control. Sensitivity and Specificity. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2009 Jun;131(6):897-8; author reply 898-900 [19461099.001]
  • (PMID = 18208807.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  • [Number-of-references] 62
  •  go-up   go-down


28. Gill PG, Luke CG, Roder DM: Clinical and pathological factors predictive of lymph node status in women with screen-detected breast cancer. Breast; 2006 Oct;15(5):640-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological factors predictive of lymph node status in women with screen-detected breast cancer.
  • Two thousand one hundred and thirty five asymptomatic invasive breast cancers detected through screening mammography were analysed to identify predictors of lymph node involvement.
  • Multivariable analysis indicated that predictors included larger tumour diameter, an infiltrating ductal or lobular histological type, multifocal disease, a palpable lesion, and a younger age at diagnosis.
  • An association also was found between nodal involvement and the presence of an extensive in situ component (EIC).
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Models, Statistical
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adult. Aged. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / epidemiology. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Female. Humans. Logistic Models. Lymphatic Metastasis / diagnosis. Mammography / statistics & numerical data. Middle Aged. Neoplasm Staging. Predictive Value of Tests. South Australia / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517164.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


29. Farshid G, Pieterse S, King JM, Robinson J: Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications. Breast J; 2005 Jan-Feb;11(1):15-22
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications.
  • Most earlier reports of mucocele-like lesions (MLL) of the breast have dealt with symptomatic cases in premenopausal women or lesions found incidentally in breast biopsies performed for other reasons.
  • The diagnosis of this lesion has special challenges in the setting of mammographic screening for breast cancer because the imaging characteristics of MLL may mimic those of ductal carcinoma in situ (DCIS), while mucinous carcinoma enters the differential diagnosis on cytologic grounds.
  • Cases with MLL as the final histologic diagnosis in our database during January 1992-June 2000 are included.
  • Correlating the cytomorphology of mucinous lesions of the breast with their mammographic appearance may permit more precise preoperative diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / radiography. Breast Neoplasms / epidemiology. Breast Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647073.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. O'Malley FP, Thomson T, Julian J, Have C, Cosby R, Gelmon K, Andrulis I, Whelan T: HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Arch Pathol Lab Med; 2008 Jan;132(1):61-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
  • CONTEXT: The development of trastuzumab has led to new therapeutic strategies for patients with breast cancer.
  • Trastuzumab has been shown to only be effective in those patients whose cancers are HER2 positive by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).
  • DESIGN: Patients with metastatic breast cancer diagnosed between 1999 and 2002 who were HER2 positive in the local laboratories were included in this study.
  • In addition, 205 locally reported HER2-negative metastatic breast cancer cases were retested centrally.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / genetics. Breast Neoplasms / diagnosis. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Predictive Value of Tests. Reproducibility of Results. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Pathol Lab Med.2008 May;132(5):730. Crosby, Roxanne [corrected to Cosby, Roxanne]
  • (PMID = 18181675.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


31. Kazakov DV, Suster S, LeBoit PE, Calonje E, Bisceglia M, Kutzner H, Rütten A, Mentzel T, Schaller J, Zelger B, Baltaci M, Leivo I, Rose C, Fukunaga M, Simpson RH, Yang Y, Carlson JA, Cavazza A, Hes O, Mukensnabl P, Vanecek T, Fidalgo A, Pizinger K, Michal M: Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast. Am J Surg Pathol; 2005 Jun;29(6):764-82
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast.
  • Our aim was fully to characterize the clinicopathologic spectrum and compare it with that seen in the breast.
  • Most lesions seem to originate from in situ lesions that may represent, using mammary pathology terminology, ductal hyperplasia, atypical ductal hyperplasia, or ductal carcinoma in situ or a combination of the three.
  • Inverse cell polarity appears to facilitate the progression of the changes similar to lesions in the breast.
  • The presence of an in situ component defines the neoplasm as primary cutaneous, but its absence does not exclude the diagnosis; although for such neoplasms, full clinical assessment is essential.
  • Mammary mucinous carcinoma involving the skin: all patients presented with lesions on chest wall, breast, axilla, and these locations can serve as clue to the breast origin.
  • Microscopically, cutaneous lesions were of both pure and mixed type, and this correlated with the primary in the breast.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Intestinal Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897743.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer; 2005 Apr 15;103(8):1631-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
  • For the current study, the authors analyzed the relation between the expression of Snail, Slug, and Sip1; the expression of MMP-2 and E-cadherin; and clinical parameters in patients with metastatic ovarian and breast carcinoma.
  • METHODS: One hundred one fresh-frozen, malignant effusions from patients who were diagnosed with gynecologic carcinomas (78 ovarian carcinomas and 23 breast carcinomas) were studied for mRNA expression of Snail, Slug, Sip1, MMP-2, and E-cadherin using reverse transcriptase-polymerase chain reaction analysis.
  • Snail mRNA and E-cadherin protein expression levels also were studied in ovarian carcinoma effusions using in situ hybridization and immunocytochemistry.
  • RESULTS: E-cadherin mRNA expression was lower in breast carcinoma (P = 0.001), whereas Snail expression was higher (P = 0.003).
  • The Snail/E-cadherin ratio (P < 0.001) and the Sip1/E-cadherin ratio (P = 0.002) were higher in breast carcinomas.
  • The Sip1/E-cadherin ratio was higher in primary ovarian carcinomas at the time of diagnosis compared with postchemotherapy ovarian carcinoma effusions (P = 0.003), higher in Stage IV tumors compared with Stage III tumors (P = 0.049), and higher in pleural effusions compared with peritoneal effusions (P = 0.044).
  • High Snail mRNA expression predicted shorter effusion-free survival (P = 0.008), disease-free survival (P = 0.03), and overall survival (P = 0.008) in patients with breast carcinoma.
  • CONCLUSIONS: Transcription factors that regulate E-cadherin were expressed differentially in metastatic ovarian and breast carcinoma.
  • Snail may predict a poor outcome in patients who have breast carcinoma metastatic to effusions.
  • This finding was in agreement with the stronger suppression of E-cadherin by Snail and Sip1 in breast carcinoma effusions, a clinical condition associated with extremely poor survival.
  • [MeSH-major] Breast Neoplasms / genetics. DNA-Binding Proteins / genetics. Drosophila Proteins / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Ovarian Neoplasms / genetics. Repressor Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Cadherins / genetics. Cadherins / metabolism. Carcinoma, Ductal / genetics. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / secondary. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15742334.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Drosophila Proteins; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / ZEB2 protein, human; 0 / snail family transcription factors; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


33. Wasif N, Garreau J, Terando A, Kirsch D, Mund DF, Giuliano AE: MRI versus ultrasonography and mammography for preoperative assessment of breast cancer. Am Surg; 2009 Oct;75(10):970-5
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI versus ultrasonography and mammography for preoperative assessment of breast cancer.
  • Mammography and ultrasonography are traditional for preoperative estimation of breast cancer size; magnetic resonance imaging (MRI) is more recent but not as well studied.
  • We compared ultrasonography, mammography, and MRI for preoperative imaging of primary breast cancer presenting as a mass in patients treated at our center over a 2-year period.
  • Of the 61 breast cancers with all three imaging modalities performed, 52 were infiltrating ductal cancer, 5 were infiltrating lobular cancer, 2 were ductal carcinoma in situ, and 2 were other histologic types.
  • We conclude that MRI is more accurate than either ultrasonography or mammography for assessment of the size of primary breast cancer presenting as a mass.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886147.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Altinoğlu EI, Russin TJ, Kaiser JM, Barth BM, Eklund PC, Kester M, Adair JH: Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano; 2008 Oct 28;2(10):2075-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer.
  • Early detection is a crucial element for the timely diagnosis and successful treatment of all human cancers but is limited by the sensitivity of current imaging methodologies.
  • PEGylated ICG-CPNPs accumulate in solid, 5 mm diameter xenograft breast adenocarcinoma tumors via enhanced retention and permeability (EPR) within 24 h after systemic tail vein injection in a nude mouse model.
  • Ex situ tissue imaging further verifies the facility of the ICG-CPNPs for deep-tissue imaging with NIR signals detectable from depths up to 3 cm in porcine muscle tissue.
  • [MeSH-major] Breast Neoplasms / pathology. Calcium Phosphates. Drug Carriers / chemistry. Indocyanine Green. Microscopy, Fluorescence / methods. Nanoparticles / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ACS Nano. 2008 Oct 28;2(10):1984-6 [19206441.001]
  • (PMID = 19206454.001).
  • [ISSN] 1936-086X
  • [Journal-full-title] ACS nano
  • [ISO-abbreviation] ACS Nano
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Drug Carriers; 97Z1WI3NDX / calcium phosphate; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


35. Liu M, Chen W, Li XR, Li JL, Wang JD, Zhang YJ, Zheng YQ, Wei LX: [Study on diagnostic accuracy of ultrasound-guided core needle breast biopsy]. Zhonghua Bing Li Xue Za Zhi; 2010 Nov;39(11):739-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on diagnostic accuracy of ultrasound-guided core needle breast biopsy].
  • OBJECTIVE: to evaluate the diagnostic accuracy of ultrasound-guided core needle biopsy of breast tumors.
  • METHODS: six hundred and sixty-seven cases of core needle biopsy of breast encountered during the period from January, 2004 to June, 2007 were retrieved from the archival file and retrospectively reviewed.
  • RESULTS: three hundred and eighty-two patients had core needle biopsy diagnosis followed by local excision, breast conservation surgery or mastectomy.
  • The rate of underestimation for ductal carcinoma-in-situ was 6/11.
  • CONCLUSION: in order to improve the diagnostic accuracy of core needle biopsy of breast tumors, recognition of the limitation of the procedure, application of immunohistochemistry and awareness of potentially rare entities are important.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Antigens, CD56 / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. False Negative Reactions. Female. Humans. Keratin-5 / metabolism. Mastectomy / methods. Membrane Proteins / metabolism. Retrospective Studies. Ultrasonography, Interventional / methods. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21215163.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Membrane Proteins
  •  go-up   go-down


36. Khalbuss WE, Ambaye A, Goodison S, Loya A, Masood S: Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature. Diagn Cytopathol; 2006 Mar;34(3):214-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature.
  • Papillary carcinoma of the male breast is very rare.
  • In this case report, we describe the cytologic, histologic, immunohistochemical, and radiological findings of a papillary carcinoma of male breast.
  • A 67-yr-old man, who had a previous history of prostatic adenocarcinoma, presented with a retroareolar painless mass.
  • There was no known history of breast cancer in his family.
  • A diagnosis of papillary lesion favoring papillary carcinoma was rendered.
  • The patient underwent lumpectomy, which showed a moderately differentiated infiltrating papillary carcinoma with adjacent areas of ductal carcinoma in situ.
  • FNAB is a useful technique in identifying male breast carcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Breast Neoplasms, Male / pathology. Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mammaglobin A. Neoplasm Metastasis. Neoplasm Proteins / analysis. Prostate-Specific Antigen / analysis. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):446-9 [8621225.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1002-5 [7866981.001]
  • [Cites] Pathology. 1997 Feb;29(1):2-6 [9094169.001]
  • [Cites] J Mol Med (Berl). 1997 Oct;75(10):758-61 [9383000.001]
  • [Cites] Indian J Pathol Microbiol. 1998 Jan;41(1):103-6 [9581085.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):498-509 [9690543.001]
  • [Cites] Acta Cytol. 1999 Sep-Oct;43(5):767-70 [10518128.001]
  • [Cites] Cancer. 1962 May-Jun;15:444-55 [14459407.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):208-12 [12752629.001]
  • [Cites] Diagn Cytopathol. 2003 Jun;28(6):329-34 [12768640.001]
  • [Cites] Arch Pathol Lab Med. 1986 Mar;110(3):189-91 [3080975.001]
  • [Cites] Tumori. 1986 Feb 28;72(1):105-8 [3952817.001]
  • [Cites] Diagn Cytopathol. 1991;7(6):581-90 [1769286.001]
  • [Cites] Am J Epidemiol. 1992 Apr 1;135(7):734-48 [1350708.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):269-77 [8425764.001]
  • [Cites] Acta Cytol. 1993 Sep-Oct;37(5):721-4 [8362586.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):336-41 [7924806.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):860-5 [8631025.001]
  • (PMID = 16548002.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108597
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 18
  • [Other-IDs] NLM/ NIHMS399894; NLM/ PMC3428056
  •  go-up   go-down


37. Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, Hainfeld J, Grogan T, Tubbs R: Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol; 2005 Nov;29(11):1505-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast.
  • Fluorescence in situ hybridization (FISH) has both excellent sensitivity and specificity in detecting HER2 gene amplification in invasive breast carcinoma.
  • The assay was performed on 94 invasive breast carcinomas, for which FISH (PathVysiontrade mark, Vysis, Downer's Grove, IL), conventional IHC (CB11), and enzyme metallography (EnzMettrade mark) results were known.
  • EnzMet is the first bright-field ISH assay in our experience that routinely and nonambiguously detects endogenous HER2 signals, essential for a reliable clinical HER2 assay, and in combination with HER2 protein enables improved diagnosis in borderline cases.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Genes, erbB-2 / immunology. Immunohistochemistry / methods. Receptor, ErbB-2 / immunology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224218.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 1R43 GM064257-01; United States / NCI NIH HHS / CA / 2R42CA83618-02; United States / NCI NIH HHS / CA / 5R42 CA083618-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


38. Zhang XL, Yang GZ, Ding HY: [Pathological study of radial sclerosing lesions]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):10-3
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the pathological diagnostic features and the differential diagnosis of radial sclerosing lesions of the breast.
  • METHODS: Morphological observation and immunohistochemistry were applied to forty-four cases of radial sclerosing lesions of the breast.
  • CONCLUSIONS: Radial sclerosing lesions of the breast possess characteristic histological features, and may be misdiagnosed as carcinoma.
  • The lesions should be differentiated from ductal carcinoma in situ, lobular neoplasia, tubular carcinoma and invasive ductal carcinoma.
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology. Keratin-5 / metabolism. Sclerosis / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Hyperplasia. Keratin-14 / metabolism. Keratins / metabolism. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388392.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-14; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


39. Dacic S: EGFR assays in lung cancer. Adv Anat Pathol; 2008 Jul;15(4):241-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was clear from the experience with targeted therapy for breast cancer that a new standardized assay procedure for assessing and predicting the effects of therapeutic agents must be developed.
  • This observation revolutionized understanding of EGFR in lung carcinogenesis and resulted in numerous retrospective studies that correlated patient's response and molecular profile of the lung adenocarcinoma.
  • Multiple methodologic approaches were used including mutational analysis, fluorescence in situ hybridization, and immunohistochemistry.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Humans. In Situ Hybridization, Fluorescence. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580100.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 61
  •  go-up   go-down


40. Bouté V, Goyat I, Denoux Y, Lacroix J, Marie B, Michels JJ: Are the criteria of Tabar and Dean still relevant to radial scar? Eur J Radiol; 2006 Nov;60(2):243-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Aschoff's center of proliferation (ACP), poses significant problems of differential diagnosis both in imagery and histology with infiltrating carcinoma.
  • The echographic diagnosis of ACP could be made in 55% of the cases but the echographic semiology lacked specificity.
  • We noticed an associated atypical epithelial hyperplasia in 28.5% of the cases, intraductal or lobular in situ carcinoma in 9% and/or a ductal invasive carcinoma in 2% of the cases.
  • [MeSH-major] Adenocarcinoma / pathology. Breast / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Calcinosis / pathology. Calcinosis / radiography. Calcinosis / ultrasonography. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Hyperplasia / radiography. Hyperplasia / ultrasonography. Incidence. Mammography. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Observer Variation. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962279.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


41. McHugh JB, Visscher DW, Barnes EL: Update on selected salivary gland neoplasms. Arch Pathol Lab Med; 2009 Nov;133(11):1763-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polymorphous low-grade adenocarcinoma can be a challenging diagnosis on biopsy specimens.
  • Evaluation of the tumor periphery and nuclear features should lead to the correct diagnosis in most cases.
  • Salivary duct carcinoma is an aggressive malignancy characterized by histologic resemblance to breast carcinoma, high-grade cytologic features, and expression of androgen receptor.
  • Benign and malignant myoepithelial neoplasms have a broad morphologic spectrum, and immunohistochemistry is important in reaching the correct diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Pleomorphic / diagnosis. Carcinoma in Situ / diagnosis. Carcinosarcoma / diagnosis. Salivary Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886710.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


42. Kumar N, Bongiovanni M, Molliet MJ, Pelte MF, Egger JF, Pache JC: Diverse glandular pathologies coexist with high-grade squamous intraepithelial lesion in cyto-histological review of atypical glandular cells on ThinPrep specimens. Cytopathology; 2009 Dec;20(6):351-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty-nine ThinPrep cervical smear (Pap) tests reported as AGC of undetermined significance and showing high-grade lesions on histology [cervical intraepithelial neoplasia (CIN) 2 or 3, endometrial or extrauterine adenocarcinoma] were reviewed retrospectively to identify the cases of high-grade squamous intraepithelial lesion with endocervical glandular extension, using the Bethesda 2001 system.
  • This included endocervical glandular extension in 63%, benign glandular pathology in 33% and pre-neoplastic or malignant glandular pathology (endocervical glandular dysplasia, adenocarcinoma in situ and metastatic breast carcinoma) in 17% cases.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Retrospective Studies. Sensitivity and Specificity. Young Adult


43. Niikura H, Yoshida H, Ito K, Takano T, Watanabe H, Aiba S, Yaegashi N: Paget's disease of the vulva: clinicopathologic study of type 1 cases treated at a single institution. Int J Gynecol Cancer; 2006 May-Jun;16(3):1212-5
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medical records were reviewed for pathologic diagnosis, patient age, associated neoplasms, type(s) of eczema, symptom duration, treatment, surgical procedures, recurrence, and length of follow-up.
  • Type 1a (intraepithelial) Paget's disease accounted for 18 patients, with 3 type 1b (invasive) cases and 1 type 1c (intraepithelial disease with underlying adenocarcinoma) case.
  • Only two patients had an associated internal malignancy: T-cell leukemia and breast cancer.
  • Inguinal lymphadenectomy is recommended in cases with question of invasion or known underlying adenocarcinoma.
  • [MeSH-major] Paget Disease, Extramammary / diagnosis. Vulva. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Aged, 80 and over. Carcinoma in Situ / diagnosis. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Staging. Neoplasms, Multiple Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803508.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Canchola AJ, Horn-Ross PL, Purdie DM: Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol; 2006 Mar 15;163(6):521-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second malignancies in women diagnosed with thyroid cancer are of concern given the young average age at diagnosis and excellent survival.
  • Follow-up was calculated from 2 months until the diagnosis of a second primary cancer, death, loss to follow-up, or December 31, 1999, whichever occurred first.
  • The incidence of invasive breast cancer was not elevated compared with California women overall (standardized incidence ratio (SIR) = 0.9, 95% confidence interval (CI): 0.7, 1.1) or when stratified by age, race/ethnicity, follow-up, or radiation treatment.
  • An excess of in situ breast cancer (SIR = 1.6, 95% CI: 1.0, 2.4), kidney cancer (SIR = 3.9, 95% CI: 2.2, 6.3), and melanoma (SIR = 2.1, 95% CI: 1.3, 3.2) limited to the first 5 years after diagnosis was observed.
  • Women with papillary thyroid cancer are at increased risk of in situ, but not invasive, breast cancer, kidney cancer, and melanoma.
  • [MeSH-major] Adenocarcinoma, Papillary / epidemiology. Breast Neoplasms / epidemiology. Kidney Neoplasms / epidemiology. Melanoma / epidemiology. Neoplasms, Second Primary / epidemiology. Thyroid Neoplasms / epidemiology


45. Gozzi G, Martinoli C, Conti GM, Ganzetti A, Bodini M, Fiorentino C, Marini UP, Santini D, Bacigalupo L: Screening mammography interpretation test: more frequent mistakes. Radiol Med; 2005 Mar;109(3):268-79
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 10 malignancies included 7 infiltrating ductal carcinomas, 1 infiltrating cribriform carcinoma, 1 infiltrating tubular carcinoma, and 1 carcinoma in situ.
  • The 13 cases of benign disease--as established by histology or long-term follow-up--mistaken for malignancies by the test participants were fibrocystic breast disease in 5 cases, surgical scar in 1 case, ABBI scar in 1 case, radial scar in 2 cases, microcalcifications that had remained stable for years in 2 cases, focal sclero-adenosis in 1 case and sclero-elastosis in 1 case.
  • Attention must be paid to these signs of focal breast disease since, if correctly evaluated, they enable the early diagnosis of low-grade carcinomas that frequently carry a favourable prognosis.
  • [MeSH-major] Breast Neoplasms / radiography. Diagnostic Errors. Mammography. Mass Screening. Radiology / standards
  • [MeSH-minor] Adenocarcinoma / radiography. Breast Diseases / surgery. Calcinosis / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal, Breast / radiography. Cicatrix / surgery. False Negative Reactions. False Positive Reactions. Female. Fibrocystic Breast Disease / radiography. Follow-Up Studies. Humans. Observer Variation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15775896.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol; 2005 Feb;16(2):273-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: HER-2/neu gene amplification has predictive value in breast cancer patients responding to trastuzumab.
  • PATIENTS AND METHODS: The frequency of HER-2/neu and Topoisomerase IIalpha gene amplification was studied in adenocarcinomas of the stomach (n=131) and the gastroesophageal junction (n=100) by chromogenic in situ hybridization (CISH).
  • Sensitivity of a gastric cancer cell line N87 with HER-2/neu amplification to trastuzumab was studied by a cell viability assay and compared with that of a HER-2 amplified breast cancer cell line SKBR-3.
  • HER-2/neu amplification was more common in the intestinal histologic type of gastric cancer (21.5%) than in the diffuse (2%) or the mixed/anaplastic type (5%, P=0.0051), but it was not associated with gender, age at diagnosis or clinical stage.
  • HER-2/neu targeting antibody trastuzumab inhibited the growth of a p185(HER-2/neu) overexpressing gastric and breast carcinoma cell lines (N87 and SKBR-3) with equal efficacy.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668283.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Isoenzymes; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


47. Yu J, Bhargava R, Dabbs DJ: Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies. Diagn Pathol; 2010;5:36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive lobular carcinomas (ILC) of breast typically demonstrate intracytoplasmic mucin.
  • We present a unique case of classical type ILC with abundant extracellular mucin and strong ERBB2 (HER2/neu) expression confirmed by immunohistochemistry and fluorescent in situ hybridization.
  • In addition, studies of tissue microarrays of 80 breast carcinomas with mucinous differentiation revealed 4 pure mucinous carcinomas showing significantly reduced E-cadherin staining without redistribution of p120 into cytoplasm.
  • The findings suggest that the presence of extracellular mucin does not exclude a diagnosis of lobular carcinoma, and the morphologic and molecular characteristics of lobular and ductal carcinomas are more complex than previously appreciated.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Carcinoma, Lobular / chemistry. Mucin-1 / analysis. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Aged. Biopsy. Cadherins / analysis. Catenins / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mastectomy, Segmental. Neoplasm Invasiveness. Tissue Array Analysis. Up-Regulation


48. Eusebi V, Millis RR: Epitheliosis, infiltrating epitheliosis, and radial scar. Semin Diagn Pathol; 2010 Feb;27(1):5-12
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis from radial scar (RS) is discussed.
  • IE can be associated with either in situ or invasive carcinoma, whereas RS being more like a process of involution is very seldom involved by a carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Diseases / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Cicatrix / pathology. Mammary Glands, Human / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Sclerosis / pathology. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306826.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Ishida M, Katsura K, Nagata A, Kijima K, Kushima R, Okabe H: [A case of primary mucinous carcinoma with endocrine differentiation of the skin]. Rinsho Byori; 2008 Jun;56(6):455-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This tumor did not accompany carcinoma in situ or invasive non-mucinous carcinoma and was difficult to differentiate from metastatic mucinous carcinoma of the skin.
  • There was no tumor in the other organs and synaptophysin and chromogranin A were sporadically shown immunohistochemically in the tumor cells; a diagnosis of primary pure MCS with endocrine differentiation was made.
  • Although endocrine differentiation is not uncommon in pure mucinous carcinoma of the breast, there have been only a few reports published on endocrine differentiation in MCS.
  • To clarify the difference and/or similarity between mucinous carcinoma of the breast and MCS, immunohistochemical and cytogenetic analyses of additional cases of MCS are required.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646630.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer; 2008 Mar 15;112(6):1325-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Methylation frequencies in the tumor samples were detected in 18% of samples for the breast cancer 1 gene BRCA1, in 43% of samples for the tissue inhibitor of metalloproteinase 3 gene TIMP-3, in 38% of samples for the cyclin-dependent kinase inhibitor 4A gene p16INK4a, in 54% of samples for the cadherin 13 gene CDH13, in 50% of samples for the death-associated protein kinase gene DAPK, in 11% of samples for the E-cadherin gene ECAD, in 25% of samples for the insulin-like growth factor binding protein 7 gene IGFBP7, in 18% of samples for the Ras association domain family 1 gene RASSF1, in 68% of samples for the adenomatous polyposis coli gene APC, in 7% of samples for the cyclin-dependent kinase inhibitor gene p15, in 18% of samples for the CD44 cell adhesion molecule gene, in 29% of samples for the human Mut-L homolog gene hMLH, in 32% of samples for the human telomerase reverse transcriptase gene hTERT, in 64% of samples for the calcitonin gene-related polypeptide alpha gene CALCA, and in 54% of samples for the estrogen receptor gene ER; however, methylation was not observed in the majority of corresponding nonmalignant tissues.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Apoptosis Regulatory Proteins / genetics. Cadherins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Case-Control Studies. CpG Islands. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Death-Associated Protein Kinases. Female. Humans. In Situ Hybridization. Insulin-Like Growth Factor Binding Proteins / genetics. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tissue Inhibitor of Metalloproteinase-3 / genetics. Ubiquitin-Protein Ligases / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18286531.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CDH17 protein, human; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / insulin-like growth factor binding protein-related protein 1; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


51. Puebla-Mora AG, Heras A, Cano-Valdez AM, Domínguez-Malagón H: Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. Ann Diagn Pathol; 2006 Aug;10(4):205-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human telomerase detected by in situ hybridization has been demonstrated to be a useful tool for the diagnosis of malignancy and has also been tested by reverse transcriptase-polymerase chain reaction in several tumors such as hepatic cell carcinoma, melanoma, colonic carcinoma, gastric carcinoma, biliary carcinoma, breast carcinoma, mesothelioma, lung carcinoma, female tract carcinoma, and prostatic carcinoma.
  • Carcinomas of cervix, endometrium, and breast have been studied by this method, but its value in prostatic carcinoma has not been explored; for that reason, we studied benign and malignant prostatic lesions by immunohistochemistry using paraffin embedded tissue.
  • [MeSH-major] Adenocarcinoma / enzymology. DNA-Binding Proteins / metabolism. Immunoenzyme Techniques / methods. Prostatic Intraepithelial Neoplasia / enzymology. Prostatic Neoplasms / enzymology. Racemases and Epimerases / metabolism. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844561.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


52. Hemminki K, Granström C, Chen B: The Swedish family-cancer database: update, application to colorectal cancer and clinical relevance. Hered Cancer Clin Pract; 2005;3(1):7-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer cases were retrieved from the Swedish Cancer Registry from 1958-2002, including over 1.2 million first and multiple primary cancers and in situ tumours.
  • Compared to previous versions, only 6.0% of deceased offspring with a cancer diagnosis lack any parental information.
  • We show one application of the Database in the study of familial risks in colorectal adenocarcinoma, with defined age-group and anatomic site specific analyses.
  • Useful risk estimates have been developed for familial breast and prostate cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):433-42 [14648711.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):969-74 [11286479.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):109-14 [14618624.001]
  • [Cites] Fam Cancer. 2003;2(2):87-93 [14574157.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):827-32 [12937124.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):39-41 [12853198.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1769-71 [12702560.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1638-44 [12496055.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):230-5 [12491486.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2428-34 [12460788.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):105-9 [12455061.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52 [12433710.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2013 [12242432.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):229-37 [11979438.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):218-28 [11979437.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):8-22 [11814067.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):743-8 [11745471.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1389-99 [11705483.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2992-3003 [11693338.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):388-91 [11161404.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2193-200 [10829038.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1312-8 [15543147.001]
  • [Cites] J Med Genet. 2004 Nov;41(11):801-7 [15520403.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):701-10 [9472113.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Int J Cancer. 1996 Nov 15;68(4):428-35 [8945611.001]
  • [Cites] Br Med Bull. 1994 Jul;50(3):527-35 [7987639.001]
  • [Cites] Cancer Detect Prev. 1995;19(3):219-33 [7750110.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] Am J Epidemiol. 1990 Jun;131(6):961-72 [2188501.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):291-4 [15069696.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3375-6 [12947078.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):809-10 [15252856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1253-6 [15247139.001]
  • [Cites] Stat Med. 2004 Apr 15;23(7):1111-30 [15057881.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):554-8 [14991577.001]
  • [Cites] J Med Genet. 2004 Feb;41(2):81-91 [14757853.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):830-8 [11606497.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):282-301 [11487538.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):807-14 [14627668.001]
  • (PMID = 20223029.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2837068
  •  go-up   go-down


53. MacGrogan G: [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture]. Ann Pathol; 2009 Jun;29(3):188-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture].
  • [Transliterated title] Pièges diagnostiques en pathologie mammaire. Cas no 1. Carcinome canalaire in situ (CCIS) de bas grade nucléaire, d'architecture papillaire, micropapillaire et cribriforme.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Neoplasms, Multiple Primary / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Cell Nucleus / ultrastructure. Diagnosis, Differential. Female. Humans. Hyperplasia. Keratins / analysis. Membrane Proteins / analysis. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619824.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


54. Chen DB, Kan X: [Cystic hypersecretory carcinoma with microinvasive carcinoma and cystic hypersecretory hyperplasia of breast: report of a case]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):54-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystic hypersecretory carcinoma with microinvasive carcinoma and cystic hypersecretory hyperplasia of breast: report of a case].
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Carcinoma / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia. Lactalbumin / metabolism. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388402.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / S100 Proteins; 9013-90-5 / Lactalbumin; Secretory breast carcinoma
  •  go-up   go-down






Advertisement